Sanofi-Synthelabo v. Apotex — Federal Circuit Upholds Plavix Patent, Holds Racemic Mixture Does Not Anticipate Isolated Enantiomer

Background

Sanofi-Synthelabo (now Sanofi) held U.S. Patent No. 4,847,265, covering clopidogrel bisulfate — the active ingredient in Plavix®, a blockbuster antiplatelet drug prescribed to reduce the risk of heart attacks and strokes. Plavix® is one of the best-selling drugs in history, generating over $7 billion in annual revenue at its peak.

Clopidogrel is the “active” enantiomer — one of two mirror-image molecular forms — of a parent compound that also exists as a racemic mixture (equal parts of both enantiomers). Sanofi’s earlier patent had disclosed the racemic compound. When Apotex filed an ANDA to market a generic version of Plavix, Sanofi filed a Hatch-Waxman patent infringement suit. Apotex argued that the ‘265 patent was invalid because the racemate described in the prior patent inherently disclosed clopidogrel (by containing it in equal proportion) and rendered the isolated enantiomer obvious.

The Court’s Holding

The Federal Circuit affirmed the validity of the ‘265 patent on both anticipation and obviousness grounds. On anticipation: the court held that prior disclosure of a racemic compound does not anticipate a claim to an isolated enantiomer because a racemic mixture is a distinct chemical species from either pure enantiomer — it has different physical properties, different pharmacokinetics, and the reference did not disclose, in an enabling way, the isolated enantiomer as a separate, useful compound. Anticipation requires that a prior art reference describe the claimed invention itself, not merely a composition that contains it in undifferentiated form.

On obviousness: the court held that isolating a specific enantiomer from a known racemate is not automatically obvious, particularly when the isolated enantiomer exhibits substantially superior and unexpected properties compared to both the racemate and the opposite enantiomer. Clopidogrel demonstrated dramatically better antiplatelet activity with fewer adverse effects than the racemate or its mirror-image counterpart — results the court found were not predictable from the prior art and supported the non-obviousness of the claimed enantiomer.

Key Takeaways

• Disclosure of a racemic mixture in prior art does not anticipate a patent claim directed to a specific isolated enantiomer — the two are chemically and legally distinct species.
• For anticipation, a prior art reference must enable the specific claimed compound and disclose it in a way a skilled person would recognize as the claimed invention — not merely contain it as an undifferentiated component of a mixture.
• Unexpected superior properties of an isolated enantiomer compared to the racemate constitute strong secondary-consideration evidence of non-obviousness.
• The ruling reinforced pharmaceutical patent strategies built around enantiomeric separation, allowing companies to obtain protection on the active form of a drug even when the racemate was previously known.

Why It Matters

Sanofi v. Apotex was one of the most financially significant pharmaceutical patent rulings of the 2000s, protecting Plavix’s market exclusivity through 2011 and preserving billions of dollars in annual revenue. The case became a touchstone for pharmaceutical patent law on the question of enantiomer patents — a critical issue as drug companies routinely develop and patent the active enantiomeric form of racemic precursors.

For the generic drug industry, the ruling clarified the demanding evidentiary showing required to challenge enantiomer patents on anticipation grounds. For brand pharmaceutical companies, it confirmed the viability of enantiomeric patent strategies, particularly when accompanied by evidence of unexpected superior pharmacological properties. The case also demonstrated how Hatch-Waxman litigation can protect enormous commercial interests while simultaneously raising fundamental scientific questions about chemical identity, novelty, and the nature of molecular chirality in drug development.